Lv1
70 积分 2024-08-19 加入
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer
7天前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
8天前
已完结
PP01.55: RASolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) vs. Docetaxel in Patients with Previously Treated RAS-Mutant NSCLC
8天前
已关闭
Precision in RNA degradation: helicases, ribosome and RNA polymerase stalling, and RNA modifications
9天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
10天前
已完结
From Undruggable to Degradable: Strategic Expansion of Targeted Protein Degradation in Cancer Therapy
12天前
已完结
Core principles of autophagy initiation mechanisms
12天前
已完结
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
14天前
已完结
FOCAD/miR-491-5p, downregulated by EGR1, function as tumor suppressor by inhibiting the proliferation and migration of gastric cancer cells
15天前
已完结
Precision in RNA degradation: helicases, ribosome and RNA polymerase stalling, and RNA modifications
21天前
已完结
皖公网安备34019202002308
